Want to see ALEC full AI Analyst Report?
Alector (ALEC) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Latozinemab | Neurodegenerative Diseases | Phase III | Enrolling By Invitation | Continuation Study for Latozinemab | Oct 18, 2023 | ― |
| Al001 | Amyotrophic Lateral Sclerosis | Phase II | Terminated | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | Sep 01, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Latozinemab | Phase III | Neurodegenerative Diseases | Enrolling By Invitation | Continuation Study for Latozinemab | Oct 18, 2023 | ― |
| Al001 | Phase II | Amyotrophic Lateral Sclerosis | Terminated | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | Sep 01, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alector (ALEC) have in its pipeline
Alector ALEC is currently developing the following drugs: Latozinemab, Al001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.